PT-141 for Men: The Off-Label Erectile Research

The short version

PT-141 for men is not approved. Bremelanotide is FDA-approved only for low sexual desire (HSDD) in premenopausal women; using it in men or for erectile dysfunction (ED) is off-label, and the evidence is early-stage. The earliest research did show erectile responses in men, and because PT-141 works in the brain while standard ED drugs work on blood flow, a combination of the two is now being tested. But one influential older study later received a formal integrity notice, and no large modern trial has established the male use. Treat everything here as investigational research, not established benefit.

Why the Male Use Is Off-Label

The approval is narrow by design: NDA 210557 covers acquired, generalized HSDD in premenopausal women, and nothing else ^[6]. Use in men, for erectile dysfunction, or in postmenopausal women is off-label and not supported by the approval. There is real early-phase data in men, but "early-phase" is the operative phrase — it is investigational, not established, and there is no regulatory finding of safety or efficacy for the male indication ^[6].

That distinction is the whole point of this page. The desire mechanism that drove the approved indication is the same central how PT-141 works in the brain action being explored in men — but a shared mechanism is not an approval.

The Early Erectile Research

The foundational pharmacology established the male signal first. In rats, nonhuman primates, and men with erectile dysfunction, systemic PT-141 produced rapid, dose-dependent erectile activity and activated hypothalamic neurons, consistent with a central mechanism ^[1]. Early development used intranasal and intravenous routes; the intranasal route was later discontinued due to pharmacokinetic variability ^[6].

In early intranasal dose-escalation research in men, a statistically significant erectile response was reported above roughly 7 mg, with dosing explored up to ~20 mg ^[6]. This established proof-of-concept for a central erectile mechanism — but proof-of-concept in early development is exactly that, not a finished indication.

The Disputed 2008 Sildenafil-Salvage Study

One frequently-cited male study must be read with its caveat attached. A 2008 randomized, double-blind, placebo-controlled trial reported that intranasal bremelanotide 10 mg produced positive clinical results in 33.5% of sildenafil non-responders versus 8.5% on placebo ^[13]. On its face that is a striking salvage signal in men who had not responded to a PDE-5 inhibitor.

But a 2023 Expression of Concern was published for this study ^[13]. An Expression of Concern is a formal editorial notice that a publication's integrity is in question. The honest handling is to disclose it every time the study is cited: treat the 33.5% vs 8.5% finding as disputed, not as a reliable result. This site flags it rather than quietly dropping it, because a researcher weighing the male evidence needs to know the caveat exists.

The Active Combination Pipeline

The current direction for the male and erectile setting is a combination, not bremelanotide alone. Because PT-141 works centrally and PDE-5 inhibitors work peripherally on blood flow, the two mechanisms are complementary in principle ^[1].

In June 2024, the developer announced initiation of a Phase 2 study (~50 patients) of bremelanotide co-administered with a PDE-5 inhibitor for erectile dysfunction in PDE-5-inhibitor non-responders, with a co-formulation IND and a potential Phase 3 planned ^[14]. This is sourced from a corporate press release, so it supports a pipeline and development-status statement only — not an efficacy claim. The male and erectile use remains off-label and investigational while that program runs.